Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOCUS-HG study of fosnetupitant for ultra-delayed chemotherapy-induced nausea and vomiting
jRCTs011250074Phase 3Recruiting
- Sponsor
- Hokkaido University Hospital
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fosnetupitant, palonosetron and dexamethasone in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Hokkaido University Hospital. Primary endpoint: Complete response to vomiting at 0-168 hours. Started Jun 2026; status: recruiting.
02
Drugs
fosnetupitantpalonosetrondexamethasone
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on jRCTs011250074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011250074.